47 completed, 7 unknown, 6 terminated, 3 withdrawn. 64 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 64 | Completed 47, Unknown 7, Terminated 6, Withdrawn 3, Not yet recruiting 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Unknown 1 |
Follow Muscle Hypertonia: new trials by email Literature Review of Muscle Hypertonia trials Research Report on Muscle Hypertonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis Arbaclofen, Placebo - Spasticity | Phase 3 | Not yet recruiting | RVL Pharmaceuticals, Inc. | 442 | 2027-01-01 | 2025-12-03 |
| Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy Magnetic Spinal Stimulation - Spastic Cerebral Palsy, Dysarthria | Phase 2 / Phase 3 | Unknown | Sociedad Argenttina de Neuromodulación | 20 | 2024-11-18 | 2023-11-21 |
| Efficacy of Extracorporeal Shock Wave Therapy in Children With Cerebral Palsy ESWT, Botulinum Toxin Type A, Serial Casting - Spasticity/Paresis, Cerebral Palsy | Phase 3 | Unknown | Kocaeli University | 40 | 2023-11-01 | 2023-11-18 |
| Therapeutic Photobiomodulation and Tretament of Spasticity Photobiomodulation, Institution's Standard Physiotherapy, Photobiomodulation Placebo - Muscle Spasticity, Cerebral Palsy | Phase 2 / Phase 3 | Completed | University of Nove de Julho | 12 | 2023-08-15 | 2026-05-01 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity With Multiple Sclerosis | Phase 3 | Terminated | Jazz Pharmaceuticals | 56 | 2021-08-16 | 2024-12-11 |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity in Participants With Multiple Sclerosis | Phase 3 | Completed | Jazz Pharmaceuticals | 68 | 2020-12-21 | 2023-07-20 |
| Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Nabiximols, Placebo - Multiple Sclerosis (MS) | Phase 3 | Terminated | Jazz Pharmaceuticals | 139 | 2020-10-01 | 2024-05-08 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy Dysport Injectable Product - Cerebral Palsy | Phase 3 | Completed | Columbia University | 12 | 2018-12-12 | 2022-06-01 |
| " Treating MS Patients With Lower Extremity Spasticity Using Dysport" Abobotulinumtoxin A - Multiple Sclerosis, Spasticity, Muscle | Phase 3 | Unknown | Neurology Center of New England P.C. | 30 | 2018-05-01 | 2018-07-13 |
| A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS Arbaclofen - Multiple Sclerosis, Spasticity, Muscle | Phase 3 | Completed | RVL Pharmaceuticals, Inc. | 323 | 2018-04-03 | 2022-08-09 |
| A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS Arbaclofen, Placebo - Multiple Sclerosis, Spasticity, Muscle | Phase 3 | Completed | RVL Pharmaceuticals, Inc. | 536 | 2018-01-28 | 2022-07-15 |
| CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3) CORETOX®, BOTOX® - Muscle Spasticity | Phase 3 | Completed | Medy-Tox | 220 | 2017-11-13 | 2021-12-07 |
| A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity Botulinum toxin A (GSK1358820), Placebo - Spasticity, Post-Stroke | Phase 3 | Completed | GlaxoSmithKline | 124 | 2017-08-02 | 2020-06-02 |
| Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients Botulinum Toxin Type A, Robot-assisted therapy, Mirror therapy - Stroke | Phase 3 | Completed | Chang Gung Memorial Hospital | 37 | 2016-05-02 | 2018-07-18 |
| Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Botulinum Toxin Injections, Placebo Injections - Hereditary Spastic Paraplegia | Phase 2 / Phase 3 | Completed | University of Campinas, Brazil | 55 | 2016-03-09 | 2017-11-07 |
| Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities Botulinum toxin type A - Cerebrovascular Accident | Phase 3 | Unknown | Chang Gung Memorial Hospital | 40 | 2015-10-01 | 2015-10-14 |
| The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke OnabotulinumtoxinA - Stroke | Phase 3 | Unknown | National Cheng-Kung University Hospital | 150 | 2015-08-01 | 2022-09-30 |
| Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity onabotulinumtoxinA - Muscle Spasticity, Stroke | Phase 3 | Withdrawn | Allergan | 2014-08-01 | 2014-08-13 |
Showing 20 of 64. Sign in to see all of them.
Muscle Spasticity (64) · Multiple Sclerosis (20) · Stroke (19) · Cerebral Palsy (17) · Hemiplegia (4) · Spinal Cord Injuries (3) · Brain Injuries, Traumatic (2) · Pain (2) · Amyotrophic Lateral Sclerosis (1) · Brain Injuries (1) · Dysarthria (1) · Hammer Toe Syndrome (1) · Marijuana Abuse (1) · Motor Neuron Disease (1) · Nervous System Diseases (1)
Muscular Diseases (64) · Musculoskeletal Diseases (64) · Neurologic Manifestations (64) · Neuromuscular Manifestations (64) · Pathological Conditions, Signs and Symptoms (64) · Signs and Symptoms (64) · Nervous System Diseases (63) · Central Nervous System Diseases (35) · Brain Diseases (32) · Autoimmune Diseases (20) · Autoimmune Diseases of the Nervous System (20) · Demyelinating Autoimmune Diseases, CNS (20) · Demyelinating Diseases (20) · Immune System Diseases (20)
Botulinum Toxins, Type A (26) · nabiximols (12) · arbaclofen placarbil (5) · Botulinum Toxins (4) · Saline Solution (4) · Baclofen (3) · abobotulinumtoxinA (3) · 4-Aminopyridine (2) · Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · rimabotulinumtoxinB (2) · 3-deoxyglycero-galacto-nonulosonic acid (1) · Hengli BTX-A (1) · Infusion Pumps (1) · Injections (1)
Jazz Pharmaceuticals (9) · Allergan (7) · GlaxoSmithKline (5) · RVL Pharmaceuticals, Inc. (5) · Chang Gung Memorial Hospital (4) · Acorda Therapeutics (2) · Ipsen (2) · Medy-Tox (2) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · Sun Pharma Advanced Research Company Limited (2) · Almirall, S.A. (1) · Assistance Publique - Hôpitaux de Paris (1) · Columbia University (1) · Daewoong Pharmaceutical Co. LTD. (1) · Elan Pharmaceuticals (1)
United States (25) · Poland (14) · United Kingdom (10) · Russia (9) · South Korea (9) · Hungary (8) · Canada (7) · Turkey (Türkiye) (6) · Czechia (5) · Taiwan (5) · Ukraine (5) · France (4) · Italy (4) · Philippines (4) · Thailand (4)
Pong Ya-Ping, MD (3) · David Jacobs, MD (2) · Emily McCusker (2) · Joseph T Hull, PhD (2) · Rozalina Dimitrova (2) · Andrew Blight (1) · Andrew Blight, MD (1) · Ariane Zoll (1) · Beom Seon Gwon, Ph.D (1) · Christine Collin, MB BS MRCP FRCP (1) · Franck Durif (1)
PMID 25475413, PMID 10896696, PMID 10946168, PMID 16777777, PMID 17086911, PMID 17355549, PMID 20358216, PMID 20569068, PMID 21362108, PMID 21878454, PMID 22791906, PMID 22878432, PMID 23468866, PMID 25592185, PMID 26030192, PMID 26812925, PMID 27631386, PMID 28726270, PMID 29330071, PMID 30554828, PMID 31691605, PMID 32497599, PMID 33206382, PMID 33483965, PMID 34339951, PMID 34828772, PMID 35412036, PMID 36136523, PMID 36306168, PMID 36832460, PMID 36861013, PMID 3809245, PMID 39106541
2019 (2), 2005 (1), 2009 (1)